EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies

Luciano J Costa, Francesca Gay, Ola Landgren, María-Victoria Mateos, Philippe Moreau, Cyrille Touzeau, Franziska Ertel, Ian McFadden, Rani Najdi, Katja Weisel

Annals of Hematology · 2025

DOI: 10.1007/s00277-024-06143-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2025. Verfasst von Luciano J Costa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham Hospital, 1802 6Th Avenue South, Birmingham, AL, 352…. Hauptthemen laut MEDLINE: Multiple Myeloma, Oligopeptides, ADP-ribosyl Cyclase 1, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although survival rates for patients with newly diagnosed multiple myeloma (NDMM) have improved over recent decades, multiple myeloma (MM) remains without a cure for most. There is increasing consensus that achievement of deep remissions, especially minimal residual disease negativity (MRD -), in frontline treatment is crucial and translates into improved survival. The standard of care (SOC) for NDMM consists at minimum of a triplet regimen of therapies, with or without an autologous stem cell transplant, or a doublet regimen for certain ineligible, particularly frail patients who may have specific limitations. Recently, anti-CD38 monoclonal antibodies (mAbs), such as daratumumab (Dara) or isatuximab (Isa), have been integrated into frontline SOC regimens. Seeking to further deepen and prolong responses, several clinical trials have commenced investigating the addition of anti-CD38 mAbs to carfilzomib, lenalidomide, and dexamethasone (KRd). These quadruplet regimens (Isa/Dara-KRd) are being evaluated in the context of evolving treatment considerations for the heterogeneous population of patients with NDMM. In clinical trials, the addition of Isa/Dara to KRd achieved high rates of deep responses and MRD - . Favorable outcomes were observed in patients with NDMM independent of age, transplant eligibility, and cytogenetic risk, while these treatments did not result in unexpected or emergent safety risks. The efficacy observed with intensified, yet well-tolerated therapy may offer further development of risk- and response-adapted therapy for individualized patient needs. This review summarizes the clinical outcomes of quadruplet-based therapy with Isa/Dara-KRd in NDMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaOligopeptidesADP-ribosyl Cyclase 1Antineoplastic Combined Chemotherapy ProtocolsAntibodies, MonoclonalHumansDexamethasoneLenalidomideClinical Trials as TopicNeoplasm, ResidualAntibodies, Monoclonal, HumanizedMembrane Glycoproteins

Stichwörter der Autor:innen

DaratumumabFrontlineIsatuximabMonoclonal antibodiesMultiple myelomaNewly diagnosed

Substanzen

carfilzomibOligopeptidesADP-ribosyl Cyclase 1Antibodies, MonoclonaldaratumumabDexamethasoneCD38 protein, humanisatuximabLenalidomideAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham Hospital, 1802 6Th Avenue South, Birmingham, AL, 35294, USA. ljcosta@uabmc.edu.
  • AOU Città Della Salute E Della Scienza Di Torino, University of Torino, Turin, Italy.
  • Division of Myeloma, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
  • University Hospital Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain.
  • The Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France.
  • Amgen GmbH, Munich, Germany.

Förderung

  • Amgen

Zitieren

APA

Costa, L. J., Gay, F., Landgren, O., Mateos, M. V., Moreau, P., Touzeau, C., Ertel, F., McFadden, I., Najdi, R., & Weisel, K. (2025). Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies. Annals of Hematology. https://doi.org/10.1007/s00277-024-06143-7

Vancouver

Costa LJ, Gay F, Landgren O, Mateos MV, Moreau P, Touzeau C, et al. Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies. Annals of Hematology. 2025. doi:10.1007/s00277-024-06143-7

BibTeX
@article{Costa2025,
  author = {Costa, Luciano J and Gay, Francesca and Landgren, Ola and Mateos, María-Victoria and Moreau, Philippe and Touzeau, Cyrille and Ertel, Franziska and McFadden, Ian and Najdi, Rani and Weisel, Katja},
  title = {Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-024-06143-7}
}
Kostenlos starten →